By exiting the US generics space, the company aims to redirect capital and executive focus toward two key growth areas: novel antibiotics and its biologicals portfolio, particularly in insulin-based ...

Dr. Makary joined NewsNation to discuss his first 100 days FDA Commissioner: 'People forget that the ‘F’ in FDA stands for food' FDA focused on fighting childhood obesity and diabetes As part of the ...

Despite healthcare spending cuts, medtech stocks like Edwards Life Sciences, Stryker, and Boston Scientific are rising, ...